Compare LEG & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEG | IMCR |
|---|---|---|
| Founded | 1883 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | LEG | IMCR |
|---|---|---|
| Price | $11.75 | $33.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $10.50 | ★ $64.30 |
| AVG Volume (30 Days) | ★ 1.4M | 469.2K |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $4,172,899,999.00 | $379,590,000.00 |
| Revenue This Year | N/A | $32.42 |
| Revenue Next Year | N/A | $11.17 |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | N/A | ★ 28.11 |
| 52 Week Low | $6.48 | $23.15 |
| 52 Week High | $12.77 | $40.72 |
| Indicator | LEG | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 41.51 |
| Support Level | $11.99 | $34.34 |
| Resistance Level | $12.77 | $35.89 |
| Average True Range (ATR) | 0.36 | 1.54 |
| MACD | -0.10 | 0.20 |
| Stochastic Oscillator | 10.09 | 31.02 |
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.